Esperion Therapeutics Inc. (NASDAQ:ESPR) saw unusually-strong trading volume on Monday . Approximately 323,545 shares were traded during mid-day trading, an increase of 19% from the previous session’s volume of 272,734 shares.The stock last traded at $11.03 and had previously closed at $10.91.

Several equities research analysts have recently weighed in on ESPR shares. JMP Securities reiterated a “buy” rating and issued a $67.00 price target on shares of Esperion Therapeutics in a report on Thursday, June 16th. Credit Suisse Group AG downgraded Esperion Therapeutics from a “neutral” rating to an “underperform” rating and reduced their price objective for the stock from $23.00 to $10.00 in a report on Wednesday, June 29th. Royal Bank Of Canada downgraded Esperion Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price objective for the stock from $30.00 to $15.00 in a report on Wednesday, June 29th. Needham & Company LLC restated a “buy” rating and set a $25.00 price objective (down from $77.00) on shares of Esperion Therapeutics in a report on Wednesday, June 29th. Finally, JPMorgan Chase & Co. downgraded Esperion Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $50.00 to $15.00 in a report on Wednesday, June 29th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $24.40.

The firm’s market capitalization is $247.82 million. The firm has a 50 day moving average price of $11.13 and a 200-day moving average price of $15.06.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.16. During the same period last year, the firm earned ($0.55) earnings per share. Equities analysts expect that Esperion Therapeutics Inc. will post ($3.36) earnings per share for the current fiscal year.

In other Esperion Therapeutics news, Director Mark E. Mcgovern acquired 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 6th. The shares were purchased at an average cost of $10.00 per share, for a total transaction of $50,000.00. Following the completion of the acquisition, the director now owns 600 shares of the company’s stock, valued at approximately $6,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.